University of Wisconsin Carbone Cancer Center

InstitutionResearch output, impact & collaborations

University of Wisconsin Carbone Cancer Center is a research organisation in Madison, US. OpenAlex records 6,211 works and 720,026 citations for it. 1,075 researchers list it as their most recent affiliation.

6,211

Works

720,026

Citations

1,075

Researchers

70.3

Avg h-index

IDs:ROR OpenAlex

How has University of Wisconsin Carbone Cancer Center's publication output changed over time?

ScholarIQpublication output · 2019–2023

Output grew0% over the shown period — from 1 works in 2019 to 1 in 2023.

201920202023

What are the most-cited papers on University of Wisconsin Carbone Cancer Center?

ScholarIQmost cited works

Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study

Sagar Lonial, Hans C. Lee, Ashraf Badros, Suzanne Trudel, Ajay K. Nooka, Ajai Chari, Al‐Ola Abdallah, Natalie S. Callander, Nikoletta Lendvai, Douglas W. Sborov, Attaya Suvannasankha, Katja Weisel, Lionel Karlin, Edward N. Libby, Bertrand Arnulf, Thierry Façon, Cyrille Hulin, K. Martin Kortüm, Paula Rodríguez‐Otero, Saad Z. Usmani, Parameswaran Hari, Rachid Baz, Hang Quach, Philippe Moreau, Peter M. Voorhees, Ira Gupta, Axel Hoos, Eric Zhi, January Baron, Trisha Piontek, Eric Lewis, Roxanne C. Jewell, Elisha J. Dettman, Rakesh Popat, Simona Degli Esposti, Joanna Opalinska, Paul G. Richardson, Adam D. Cohen

The Lancet Oncology. 2019806 Citations

Ide-cel or Standard Regimens in Relapsed and Refractory Multiple Myeloma

Paula Rodríguez‐Otero, Sikander Ailawadhi, Bertrand Arnulf, Krina K. Patel, Michèle Cavo, Ajay K. Nooka, Salomon Manier, Natalie S. Callander, Luciano J. Costa, Ravi Vij, Nizar J. Bahlis, Philippe Moreau, Scott R. Solomon, Michel Delforge, Jesús G. Berdeja, Anna Truppel-Hartmann, Zhihong Yang, Linda Favre‐Kontula, Fan Wu, Julia Piasecki, Mark Cook, Sergio Giralt

New England Journal of Medicine. 2023733 CitationsOPEN ACCESS

Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial

Shaji Kumar, Susanna Jacobus, Adam D. Cohen, Matthias Weiss, Natalie S. Callander, Avina K. Singh, Terri L. Parker, Alexander Menter, Xuezhong Yang, Benjamin M. Parsons, Pankaj Kumar, Prashant Kapoor, Aaron S. Rosenberg, Jeffrey A. Zonder, Edward A. Faber, Sagar Lonial, Kenneth C. Anderson, Paul G. Richardson, Robert Z. Orlowski, Lynne I. Wagner, S. Vincent Rajkumar

The Lancet Oncology. 2020259 CitationsOPEN ACCESS